[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 47 of about 47
1. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol; 2009 Mar;112(3):543-52
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.
  • OBJECTIVES: After surgical debulking and volume-directed irradiation of the pelvis/para-aortic lymph nodes, treatment was randomized to compare recurrence-free survival (RFS) and toxicity between two chemotherapy regimens for the treatment of women with advanced stage endometrial carcinoma.
  • METHODS: Treatment was randomized between 6 cycles of cisplatin [C] (50 mg/m(2)) and doxorubicin [D] (45 mg/m(2)) with or without paclitaxel [P] (160 mg/m(2)).
  • RESULTS: Of 659 patients enrolled following surgery, 552 eligible patients were randomized to chemotherapy after irradiation.
  • Accrual closed to Stage IV patients in June, 2003.
  • Approximately 80% completed six cycles of chemotherapy.
  • The hazard of recurrence or death relative to the CD arm stratified by stage is 0.90 (95% CI is 0.69 to 1.17, p=0.21, one-tail).
  • However, in subgroup analysis, CDP was associated with a 50% reduction in the risk of recurrence or death among patients with gross residual disease (95% CI: 0.26 to 0.92).
  • Stage, residual disease, histology/grade, positive para-aortic node and cytology, pelvic metastases and age were significantly associated with RFS.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108877.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA101165-04; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA027469-22; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS102171; NLM/ PMC4459781
  •  go-up   go-down


2. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, Freeman EW, Gracia CR, DeMichele A: Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer; 2010 Feb 1;116(3):592-9
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In late reproductive-aged breast cancer survivors, there is a need for real-time biomarkers of postchemotherapy ovarian function.
  • The authors tested whether AMH and inhibin B were impacted by breast cancer treatment by comparing cancer survivors to age-matched control women and determined the association between these hormones and postchemotherapy menstrual pattern.
  • METHODS: Breast cancer patients (n = 127) with American Joint Committee on Cancer stage I to III disease who were premenopausal at diagnosis were enrolled postchemotherapy and observed.
  • The primary endpoint was chemotherapy-related amenorrhea (CRA) (> or = 12 months of amenorrhea after chemotherapy).
  • Associations between hormones, CRA status, and change in CRA status over time were assessed.
  • RESULTS: The median age of the patients at chemotherapy was 43.2 years (range, 26.7-57.8 years).
  • At enrollment, median follow-up since chemotherapy was 2.1 years, and 55% of subjects had CRA.
  • AMH was significantly lower (P = .03) and FSH was significantly higher (P = .04) in menstruating subjects who developed subsequent CRA.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society.
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5307-14 [14602766.001]
  • [Cites] Hum Reprod. 2003 Nov;18(11):2368-74 [14585889.001]
  • [Cites] Cancer. 1978 Jun;41(6):2084-7 [418867.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):4043-7 [6451282.001]
  • [Cites] NCI Monogr. 1986;(1):105-9 [3534581.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):624-30 [3098415.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):771-7 [7889613.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1718-29 [8622093.001]
  • [Cites] Menopause. 2004 Nov-Dec;11(6 Pt 1):601-6 [15545787.001]
  • [Cites] Hum Reprod Update. 2005 Jan-Feb;11(1):69-89 [15569700.001]
  • [Cites] Fertil Steril. 2005 Feb;83(2):383-92 [15705379.001]
  • [Cites] Menopause. 2005 Mar;12(2):128-35 [15772558.001]
  • [Cites] Hum Reprod. 2005 Apr;20(4):923-7 [15640257.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2444-7 [16735701.001]
  • [Cites] Hum Reprod. 2006 Oct;21(10):2583-92 [16820385.001]
  • [Cites] Hum Reprod Update. 2006 Nov-Dec;12(6):685-718 [16891297.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5769-79 [17130515.001]
  • [Cites] Fertil Steril. 2007 Jan;87(1):101-6 [17109858.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1808-16 [17533402.001]
  • [Cites] Hum Reprod Update. 2007 Nov-Dec;13(6):559-65 [17630397.001]
  • [Cites] Cancer Invest. 2008 Apr-May;26(3):286-95 [18317970.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2129-34 [18334591.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3478-83 [18593767.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2385-97 [18819158.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2365-70 [10561298.001]
  • [Cites] Eur J Cancer. 2000 Jan;36(1):43-8 [10741293.001]
  • [Cites] Climacteric. 2001 Dec;4(4):267-72 [11770182.001]
  • [Cites] Fertil Steril. 2002 Feb;77(2):357-62 [11821097.001]
  • [Cites] Breast Cancer Res Treat. 2003 Nov;82(2):103-11 [14692654.001]
  • (PMID = 19918920.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG012745-14; United States / NICHD NIH HHS / HD / HD007440-12; United States / NICHD NIH HHS / HD / T32 HD007440; United States / NIA NIH HHS / AG / AG012745-14; United States / NICHD NIH HHS / HD / T32 HD007440-12; United States / NIA NIH HHS / AG / R01 AG012745; United States / NICHD NIH HHS / HD / 5-T32-HD007400-12
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / inhibin B; 094ZI81Y45 / Tamoxifen; 57285-09-3 / Inhibins; 80497-65-0 / Anti-Mullerian Hormone; 9002-68-0 / Follicle Stimulating Hormone
  • [Other-IDs] NLM/ NIHMS153276; NLM/ PMC2815049
  •  go-up   go-down


3. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res; 2005 Oct 1;65(19):8961-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have determined the methylation frequencies of 24 CpG islands of genes associated with DNA damage responses or with ovarian cancer in 106 stage III/IV epithelial ovarian tumors.
  • We have analyzed this data for whether there is evidence of a CpG island methylator phenotype or associations of CpG island methylation with response to chemotherapy in advanced ovarian cancer.
  • Methylation of at least one of the group of genes involved in DNA repair/drug detoxification (BRCA1, GSTP1, and MGMT) was associated with improved response to chemotherapy (P = 0.013).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CpG Islands. DNA (Cytosine-5-)-Methyltransferase / genetics. DNA Methylation. Female. Genotype. Humans. Middle Aged. Neoplasm Staging. Polymorphism, Genetic


Advertisement
4. Schleinitz MD, DePalo D, Blume J, Stein M: Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med; 2006 Dec;21(12):1253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Black, older, and less affluent women are less likely to receive adjuvant breast cancer therapy than their counterparts.
  • OBJECTIVE: To ascertain utilities from women of diverse backgrounds for the different stages of, and treatments for, breast cancer and to determine whether a treatment decision modeled from utilities is associated with socio-demographic characteristics.
  • PARTICIPANTS: A stratified sample (by age and race) of 156 English-speaking women over 25 years old not currently undergoing breast cancer treatment.
  • DESIGN AND MEASUREMENTS: We assessed utilities using standard gamble for 5 breast cancer stages, and time-tradeoff for 3 therapeutic modalities.
  • We incorporated each subject's utilities into a Markov model to determine whether her quality-adjusted life expectancy would be maximized with chemotherapy for a hypothetical, current diagnosis of stage II breast cancer.
  • RESULTS: Median utilities for the 8 health states were: stage I disease, 0.91 (interquartile range 0.50 to 1.00); stage II, 0.75 (0.26 to 0.99); stage III, 0.51 (0.25 to 0.94); stage IV (estrogen receptor positive), 0.36 (0 to 0.75); stage IV (estrogen receptor negative), 0.40 (0 to 0.79); chemotherapy 0.50 (0 to 0.92); hormonal therapy 0.58 (0 to 1); and radiation therapy 0.83 (0.10 to 1).
  • Utilities for early stage disease and treatment modalities, but not metastatic disease, varied with socio-demographic characteristics.
  • One hundred and twenty-two of 156 subjects had utilities that maximized quality-adjusted life expectancy given stage II breast cancer with chemotherapy.
  • Age over 50, black race, and low household income were associated with at least 5-fold lower odds of maximizing quality-adjusted life expectancy with chemotherapy, whereas women who were married or had a significant other were 4-fold more likely to maximize quality-adjusted life expectancy with chemotherapy.
  • CONCLUSIONS: Differences in utility for breast cancer health states may partially explain the lower rate of adjuvant therapy for black, older, and less affluent women.
  • Further work must clarify whether these differences result from health preference alone or reflect women's perceptions of sources of disparity, such as access to care, poor communication with providers, limitations in health knowledge or in obtaining social and workplace support during therapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] WMJ. 1999 Dec;98(8):37-9 [10639893.001]
  • [Cites] J Gen Intern Med. 2005 Jan;20(1):38-44 [15693926.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1577-85 [11401308.001]
  • [Cites] Natl Vital Stat Rep. 2001 Sep 21;49(8):1-113 [11591077.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):471-3 [11929941.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] South Med J. 2002 Oct;95(10):1145-8 [12425498.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Cancer Metastasis Rev. 2003 Mar;22(1):55-65 [12716037.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):21-31 [14531494.001]
  • [Cites] BMC Med Inform Decis Mak. 2001;1:2 [11545684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42 [14697418.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):184-94 [15009798.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Decis Making. 2000 Jan-Mar;20(1):72-8 [10638539.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):90-7 [12529090.001]
  • [Cites] J Eval Clin Pract. 2003 Feb;9(1):69-82 [12558704.001]
  • [Cites] Med Decis Making. 2003 Mar-Apr;23(2):167-76 [12693879.001]
  • [Cites] Prev Med. 2004 Jul;39(1):1-10 [15207980.001]
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Clin Prostate Cancer. 2004 Jun;3(1):31-7 [15279688.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] Med Decis Making. 1982 Winter;2(4):449-62 [7182703.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S190-204 [2522159.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] Med Decis Making. 1993 Jul-Sep;13(3):212-7 [8412549.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1395-402 [8839544.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(3):261-73 [8877006.001]
  • [Cites] Breast Cancer Res Treat. 1996;40(1):65-74 [8888153.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • [Cites] Med Decis Making. 1997 Jan-Mar;17(1):21-32 [8994148.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):136-41 [9107608.001]
  • [Cites] Oncol Nurs Forum. 1998 Apr;25(3):555-62 [9568610.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):887-95 [9644705.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15 [10451447.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1047-53 [10526998.001]
  • [Cites] Med Care. 2005 Feb;43(2):141-8 [15655427.001]
  • [Cites] Med Care. 2000 Sep;38(9 Suppl):II160-4 [10982102.001]
  • (PMID = 16961753.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NICHD NIH HHS / HD / HD43447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1924747
  •  go-up   go-down


5. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int; 2002 Dec;62(6):1933-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
  • BACKGROUND: Fabry disease, a lysosomal storage disease caused by deficient lysosomal alpha-galactosidase A activity, is characterized by globotriaosylceramide (GL-3) accumulation in multiple cell types, particularly the vasculature, leading to end organ failure.
  • With the advent of recombinant protein synthesis technology, enzyme replacement therapy has become a viable alternative to dialysis or renal transplantation, previously the only available treatment options for end-stage renal disease.
  • METHODS: The pre- and post-treatment renal biopsies were analyzed from fifty-eight Fabry patients enrolled in a Phase 3 double-blind, randomized, placebo-controlled trial followed by a six-month open label extension study of the recombinant human enzyme, alpha-galactosidase A (r-halphaGalA), administered IV at 1 mg/kg biweekly.
  • The purpose of this investigation was to detail the pathologic changes in glycosphingolipid distribution and the pattern of post-treatment clearance in the kidney.
  • RESULTS: Baseline evaluations revealed GL-3 accumulations in nearly all renal cell types including vascular endothelial cells, vascular smooth muscle cells, mesangial cells and interstitial cells, with particularly dense accumulations in podocytes and distal tubular epithelial cells.
  • After 11 months of r-halphaGalA treatment there was complete clearance of glycolipid from the endothelium of all vasculature as well as from the mesangial cells of the glomerulus and interstitial cells of the cortex.
  • Podocytes and distal tubular epithelium also demonstrated evidence for decreased GL-3, although this clearance was more limited than that observed in other cell types.
  • No evidence of immune complex disease was found by immunofluorescence despite circulating anti-r-halphaGalA IgG antibodies.
  • CONCLUSIONS: These findings indicate a striking reversal of renal glycosphingolipid accumulation in the vasculature and in other renal cell types, and suggest that long-term treatment with r-halphaGalA may halt the progression of pathology and prevent renal failure in patients with Fabry disease.
  • [MeSH-major] Fabry Disease / drug therapy. Fabry Disease / metabolism. Trihexosylceramides / metabolism. alpha-Galactosidase / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Antigen-Antibody Complex / analysis. Biopsy. Capillaries / metabolism. Capillaries / pathology. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Epithelial Cells / immunology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Extracellular Matrix / metabolism. Female. Glomerular Mesangium / blood supply. Glomerular Mesangium / immunology. Glomerular Mesangium / pathology. Humans. Male. Muscle, Smooth, Vascular / metabolism. Muscle, Smooth, Vascular / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12427118.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 MO1 RR00071; United States / NICHD NIH HHS / HD / 5 P30 HD28822; United States / NIDDK NIH HHS / DK / R29 DK 34045
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Trihexosylceramides; 71965-57-6 / globotriaosylceramide; EC 3.2.1.22 / alpha-Galactosidase
  •  go-up   go-down


6. Huang HQ, Jiang WQ, Wang W, Xu GC, Zhang L, He YJ, Sun XF, Zhou ZM, Liu DG, Xu RH, Lin TY, Teng XY, Liu MZ, Su YS, Li YH, Lin XB, Guan ZZ: [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality]. Ai Zheng; 2002 Dec;21(12):1345-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality].
  • BACKGROUND & OBJECTIVE: Hodgkin's disease (HD) is a chemo- and radio-sensitive hematologic malignancy.
  • At present, improvement of cure rate, reduction of long-term toxicity, and maintenance of good quality of life are the major issues in the treatment of HD.
  • METHODS: The results of 295 patients with histology-proven HD from 1970 to 2000, especially from 1980 to 2000 were analyzed.
  • RESULTS: A total of 295 HD patients were treated by chemotherapy-predominant comprehensive modality.
  • The 5, 10, and 20 years overall survival for 295 HD patients were 63.5%, 55.8%, and 47.1%, respectively, with median survival time of 172.3 months (28-351.9 months) at the median follow-up time of 42.9 months (17-351.9 months).
  • The 5, 10, and 20 years overall survival and disease-free survival were 79.6%, 74.5%, and 66.8% as well as 74.5%, 69.4%, and 69.4% respectively for the patients treated with regular chemotherapy and radiotherapy from 1980 to 2000.
  • Multivariate analysis demonstrated that age over 45-year-old, B symptoms and stage III/IV were the main prognostic factors (P = 0.000, P = 0.035, and P = 0.047) in this clinical study.
  • The prognosis of the patients with stage I/II and nodular sclerosis was better in comparison to stages III/IV and other histologic subtypes.
  • CONCLUSIONS: Chemotherapy-predominant combined with involved fields irradiation play an important role in HD treatment with promising long term survival and lower late toxicities.
  • [MeSH-major] Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Clinical Trials as Topic. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12520745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM: High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol; 2004 Sep;126(6):815-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
  • A very short, intensive paediatric chemotherapy programme was tested in a consecutive monoinstitutional group of 22 adult Burkitt's lymphoma (BL) patients.
  • After a 5-week induction phase of weekly infusions consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX) plus leukovorin rescue, and intrathecal MTX or cytarabine (ARA-C), a consolidation phase including HD ARA-C plus cisplatin was given.
  • Responding patients achieving less than complete response (CR) after completion of the initial induction phase, were promptly shifted to a high-dose, stem cell supported sequential chemotherapy schema (R-HDS).
  • PATIENT CHARACTERISTICS: median age, 35.5 (range 18-76) years; Ann Arbor stage I-II/III-IV, 11/11; bulky disease, 15 patients; LDH > or = 460 U/l, 11 patients.
  • The median duration of the chemotherapy programme was 62 d (range, 43-94 d).
  • Seventeen patients achieved a CR (77%), one patient died of progressive disease and four partial responders following induction were converted to CR following R-HDS.
  • Of 17 patients in CR, one died of infectious toxicity while in CR, and one relapsed at 30 months and died of progressive disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352985.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Zapatero A, López MA, Cerezo L, De Vidales CM, MarIn A, Pérez-Torrubia A: Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era. Hematology; 2002 Feb;7(1):43-50
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era.
  • PURPOSE: To analyse the long term outcome, pattern of failure and treatment related complications after radiation therapy (RT) with or without chemotherapy for stage I-III Hodgkin's disease (HD).
  • MATERIAL AND METHODS: Detailed records from 86 patients with stage I-III HD treated between 1989 and 1998, were retrospectively reviewed.
  • Seventeen patients with favourable stage I-IIA were treated with RT alone, and the remaining 69 patients with combined modality treatment (CMT).
  • Patients treated with RT received extended-field or subtotal nodal irradiation (STNI) to a total dose of 36-54 Gy, and patients with CMT, received involved-field irradiation to a lower doses, 26-40 Gy.
  • The median follow-up time was 50 months (range 16-180).
  • RESULTS: The 10-year overall survival (OS) for the whole group was 96% (SE 2%), 100% for stage I, 95% for stage II and 100% for stage III patients.
  • Of potential prognostic factors analysed for statistical significance, only the response to chemotherapy (p=0.0393) was found to influence significantly OS rates.
  • Salvage treatment was effective in 10 of the 12 relapsed patients.
  • The 10-year freedom from treatment failure (FFTF) was 79% (SE 6%).
  • Although 8 (9.6%) of the 83 surviving patients developed late effects that could represent toxicity from the treatment, no patient died of late complications.
  • CONCLUSIONS: RT alone for favourable early stage HD attains good survival rates with a modest treatment related morbidity.
  • For patients with unfavourable stage II and stage III HD, CMT with limited RT provides a good to excellent prognosis.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171776.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA, AGO-Ovar/AIO, EBMT: Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol; 2007 Sep 20;25(27):4187-93
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
  • PURPOSE: Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy is uncommon.
  • A randomized trial comparing high-dose sequential chemotherapy with peripheral blood stem cell (PBSC) support with platinum-based combination chemotherapy was conducted to investigate whether dose-intensification improves outcome.
  • PATIENTS AND METHODS: One hundred forty-nine patients with untreated ovarian cancer were randomly assigned after debulking surgery to receive standard combination chemotherapy or sequential high-dose (HD) treatment with two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support.
  • HD melphalan was added to the final cycle.
  • The median age was 50 years (range, 20 to 65 years) and International Federation of Gynecology and Obstetrics stage was IIb/IIc in 4%, III in 78%, and IV in 17%.
  • RESULTS: Seventy-six percent of patients received all five cycles in the HD arm and the main toxicities were neuro-/ototoxicity, gastrointestinal toxicity, and infection and one death from hemorrhagic shock.
  • After a median follow-up of 38 months, the progression-free survival was 20.5 months in the standard arm and 29.6 months in the HD arm (hazard ratio [HR], 0.84; 95% CI, 0.56 to 1.26; P, .40).
  • Median overall survival (OS) was 62.8 months in the standard arm and 54.4 months in the HD arm (HR, 1.17; 95% CI, 0.71 to 1.94; P, .54).
  • CONCLUSION: This is the first randomized trial comparing sequential HD versus standard dose chemotherapy in first-line treatment of patients with advanced ovarian cancer.
  • We observed no statistically significant difference in progression-free survival or OS and conclude that HD chemotherapy does not appear to be superior to conventional dose chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cyclophosphamide / administration & dosage. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Paclitaxel / administration & dosage. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Melphalan / administration & dosage. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4157-8 [17698802.001]
  • (PMID = 17698804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan
  •  go-up   go-down


10. Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E: Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer; 2000 May 1;88(9):2142-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
  • BACKGROUND: Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD).
  • Cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) is a hybrid chemotherapy in which cyclophosphamide is substituted for mechlorethamine, an agent that has been implicated as the cause of secondary malignancies.
  • METHODS: Seventy-three patients (37 males and 36 females; median age, 35 years) diagnosed with Stage III or IV HD or Stage II with bulky disease, B-symptoms, elevated erythrocyte sedimentation rate, or hilar adenopathy were treated with 8 courses of C-MOPP/ABV at a single institution during a 6-year period.
  • Radiotherapy (RT) was administered when bulky disease or residual masses were present.
  • Endpoints of the study were response to therapy, failure free survival (FFS), overall survival (OS), and toxicity.
  • After chemotherapy, 57 patients (78%) reached CR.
  • Two patients died during treatment because of sepsis and four due to disease progression.
  • CONCLUSIONS: C-MOPP/ABV induces CR with acceptable toxicity in a high proportion of advanced HD patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Bleomycin / administration & dosage. Bleomycin / adverse effects. Confidence Intervals. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Radiotherapy, Adjuvant. Remission Induction. Survival Rate. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813727.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


11. Klauber-Demore N, Kuzmiak C, Rager EL, Ogunrinde OB, Ollila DW, Calvo BF, Kim HJ, Meyer A, Dees C, Graham M 2nd, Collichio FA, Sartor CI, Metzger R, Carey LA: High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Am J Surg; 2004 Oct;188(4):386-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
  • BACKGROUND: The purpose of this study was to evaluate the efficacy of high-resolution axillary ultrasound in detecting axillary lymph node metastases after neoadjuvant chemotherapy in patients with locally advanced breast cancer.
  • METHODS: Fifty-three patients with stage II or III breast cancer undergoing neoadjuvant chemotherapy who had a physical examination, high-resolution axillary ultrasound, and axillary lymph node dissection from January 1999 to September 2003 were included in this study.
  • CONCLUSIONS: A negative post-neoadjuvant chemotherapy high-resolution axillary ultrasound or physical examination does not predict pathologic node status, and this test has limited value in this setting.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Axilla. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15474431.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 5K12 HD001441; United States / NCI NIH HHS / CA / CA58223; United States / NCRR NIH HHS / RR / M01 RR00046
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


12. Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M: Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol; 2000 Mar;30(3):146-52
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
  • BACKGROUND: The main form of cytotoxic treatment for advanced Hodgkin's disease (HD) is conventional dose multiagents chemotherapy.
  • As HD is not common in Japan, we conducted a phase II study of the commonly used combination chemotherapy (CCT) regimen established in the West for Japanese patients with advanced HD to confirm the efficacy and safety.
  • METHOD: Between October 1989 and February 1993, a multicenter phase II study of alternating CCT C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, vinblastine, bleomycin, dacarbazine) to evaluate its clinical usefulness for clinical stage (cS) II-IV HD was conducted by the Lymphoma Study Group of the Japan Clinical Oncology Group.
  • For 40 cS II and 27 cS III/IV patients the response rate was 95.0% with 90.0% CR and 88.9% with 74.1% CR, respectively.
  • Those of cS II and cS III/IV were 92.5 and 73.1%, respectively.
  • There was no significant difference between cS II and cS III/IV (p = 0.1025).
  • Those of cS II and cS III/IV were 77.5 and 65.7%, respectively.
  • There was no significant difference between cS II and cS III/IV (p = 0.2483).
  • There was GPT elevation in 4.5%, nausea/vomiting in 11.9% and CNS in 1.5% of patients, but there was no treatment-related death.
  • CONCLUSION: The C-MOPP/ABVd regimen for Japanese patients with advanced HD is considered to be one of the effective CCTs according to the results of the present phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Prednisolone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Survival Rate. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10798542.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ABVD protocol; CMOPP protocol
  •  go-up   go-down


13. Proctor SJ, Mackie M, Dawson A, White J, Prescott RJ, Lucraft HL, Angus B, Jackson GH, Lennard AL, Hepplestone A, Taylor PR: A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer; 2002 Apr;38(6):795-806
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III).
  • The aim of the study was to identify all patients with poor risk Hodgkin's disease (HD) using a numerical prognostic index in a defined population and to recruit them into a trial of intensive chemotherapy prednisolone, vinblastine, doxorubicin, chlorambucil, etoposide, bleomycin, vincristine, procarbazine (PVACE-BOP)x3+autotransplant (Arm A) versus PVACE-BOPx5 (Arm B) in first remission.
  • In 10 years, the Scotland and Newcastle Lymphoma Group (SNLG) registered 930 patients with HD of whom 178 (19%) were identified as 'poor risk' by the SNLG index and were aged 16-59 years.
  • Of the 120 confirmed poor risk HD cases, all completed PVACE-BOPx3 with a 93% Complete Response/unconfirmed Complete Response (CR/CRu) rate.
  • With a median follow-up of 6 years, both arms of the trial have a similar time to treatment failure (TTF) (Arm A 79%+/-11 versus 85%+/-7 Arm B, P=0.35).
  • Advanced stage 'good risk' patients not included in the trial receiving standard therapy with CLVPP or ABVD had a 75% 5-year survival.
  • The study demonstrates that PVACE-BOP therapy in the poorest risk group (58% had an IPI>/=3) produces excellent CR rates (93%) and overall survival with minimal toxicity, and that the substitution of autotransplant in first CR does not improve outcome.
  • The placing of a randomised control trial within the context of a population-based study of HD enhances the validity of the outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation / methods. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy / methods. Female. Follow-Up Studies. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Recurrence. Risk Factors. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11937314.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


14. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA: Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol; 2004 Jun 15;22(12):2303-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
  • PURPOSE: To determine patterns of local-regional recurrence (LRR) and ipsilateral breast tumor recurrence (IBTR) among patients treated with breast conservation therapy after neoadjuvant chemotherapy.
  • PATIENTS AND METHODS: Between 1987 and 2000, 340 cases of breast cancer were treated with neoadjuvant chemotherapy followed by conservative surgery and radiation therapy.
  • Clinical stage at diagnosis (according to the 2003 American Joint Committee on Cancer system) was I in 4%, II in 58%, and III in 38% of patients.
  • RESULTS: At a median follow-up period of 60 months (range, 10 to 180 months), 29 patients had developed LRR, 16 of which were IBTRs.
  • Variables that positively correlated with IBTR and LRR were clinical N2 or N3 disease, pathologic residual tumor larger than 2 cm, a multifocal pattern of residual disease, and lymphovascular space invasion in the specimen.
  • CONCLUSION: Breast conservation therapy after neoadjuvant chemotherapy results in acceptably low rates of LRR and IBTR in appropriately selected patients, even those with T3 or T4 disease.
  • Advanced nodal involvement at diagnosis, residual tumor larger than 2 cm, multifocal residual disease, and lymphovascular space invasion predict higher rates of LRR and IBTR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Mastectomy, Segmental. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197191.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


15. Brenot-Rossi I, Bouabdallah R, Di Stefano D, Bardou VJ, Stoppa AM, Camerlo J, Sauvan R, Gastaut JA, Pasquier J: Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy. Eur J Nucl Med; 2001 Oct;28(10):1482-8
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy.
  • Evaluation of the response to therapy is important for optimal selection of treatment strategy in patients with Hodgkin's disease (HD).
  • Refractory disease requires intensive high-dose chemotherapy, whereas unnecessary treatment should be avoided in patients in complete remission.
  • The purpose of this study was to evaluate the contribution of gallium-67 scintigraphy in predicting the clinical outcome in patients with HD and mediastinal involvement on the basis of scan results at the end of chemotherapy.
  • Seventy-four patients with HD and mediastinal involvement were retrospectively investigated with 67Ga scintigraphy 72 h after injection of 220 MBq 67Ga citrate (planar and single-photon emission tomographic studies) following the completion of chemotherapy.
  • At the same time, they all underwent computed tomography (CT).
  • The disease status was newly diagnosed disease in 64 of the patients and relapse in 10.
  • Forty-one patients had stage I or II disease and 33 patients had stage III or IV disease.
  • Twenty-two patients had bulky disease on initial diagnosis.
  • At the end of chemotherapy, all 74 patients showed regression of the mass by more than 50% (50%-100%) on CT.
  • Patients were divided into two groups according to the positivity or negativity of the gallium scan after chemotherapy: 61 patients had negative and 13 patients had positive gallium scans.
  • In the gallium-positive group, 84.6% of the patients had recurrent disease and 61.5% were alive after intensive chemotherapy.
  • Disease-free survival differed significantly between patients with positive and patients with negative gallium scans at the end of chemotherapy (P<0.0001).
  • It is concluded that even if gallium scan is performed at the end of chemotherapy, it can predict outcome.
  • Alternative therapy may be required on the basis of gallium scan results obtained after treatment.
  • [MeSH-major] Citrates. Gallium. Hodgkin Disease / mortality. Hodgkin Disease / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685490.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


16. Kovács AF, Mose S, Böttcher HD, Bitter K: Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol; 2005 Jan;181(1):26-34
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
  • BACKGROUND: To examine the feasibility and efficacy of weekly docetaxel with concurrent radiation as postoperative treatment in a multimodality approach to oral and oropharyngeal cancer.
  • PATIENTS AND METHODS: 94 patients (Table 1) with primary resectable squamous cell carcinoma of the oral cavity and oropharynx (UICC stage I 14%, II 15%, III 18%, IV 53%; Table 2) were treated with a multimodality therapy program consisting of neoadjuvant intra-arterial high-dose chemotherapy (cisplatin 150 mg/m(2) with parallel systemic sodium thiosulfate 9 g/m(2) for neutralization), followed by surgery of the primary and neck, and postoperative concurrent radiation and chemotherapy with weekly docetaxel (20-30 mg/m(2); Table 3).
  • RESULTS: At a median follow-up of 4 years, the 5-year survival rate for all 94 patients was 80%, and disease-free survival was 73% (Figures 1 and 2).
  • Among patients with advanced disease (stage III and IV), survival was 83 and 59%, respectively (Figure 4).
  • CONCLUSIONS: Concurrent radiation and chemotherapy with weekly docetaxel is a feasible postoperative treatment in a multimodality approach to oral and oropharyngeal cancer, resulting in high overall and disease-free survival.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Radiotherapy, Adjuvant. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Head / pathology. Humans. Infusions, Intravenous. Injections, Intra-Arterial. Male. Middle Aged. Neck / pathology. Neck Dissection. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Care. Radiotherapy Dosage. Survival Analysis. Thiosulfates / administration & dosage. Thiosulfates / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660190.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0 / Thiosulfates; 15H5577CQD / docetaxel; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL: Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys; 2002 Jul 15;53(4):880-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
  • PURPOSE: To compare the pathologic factors associated with postmastectomy locoregional recurrence (LRR) in breast cancer patients not receiving radiation who were treated with neoadjuvant chemotherapy (NEO) vs. adjuvant chemotherapy (ADJ).
  • METHODS AND MATERIALS: We retrospectively analyzed the rates of LRR of subsets of women treated in prospective trials who underwent mastectomy and received chemotherapy but not radiation.
  • These trials were designed to answer chemotherapy questions.
  • In the NEO group, 55% had clinical Stage IIIA or higher vs. 9% in the ADJ group (p <0.001, chi-square test).
  • RESULTS: Despite the more advanced clinical stage in the NEO group, the pathologic size of the primary tumor and the number of positive lymph nodes (+LNs) were significantly less in the NEO group than in the ADJ group (p <0.001 for both comparisons).
  • Most failures in this NEO subgroup had clinical Stage III disease.
  • In a subset of NEO and ADJ patients matched for clinical stage, no significant differences were found in the rates of LRR according to primary tumor size and number of +LNs when these variables were analyzed independently.
  • CONCLUSION: The rates of postmastectomy LRR for any pathologic tumor size are higher for patients treated with initial chemotherapy than for patients treated with initial surgery.
  • Radiotherapy should be offered to all patients with > or =4 +LNs, tumor size >5 cm, or clinical Stage IIIA or greater disease, regardless of whether they receive neoadjuvant or postoperative chemotherapy.
  • The information assessing LRR rates in patients with clinical Stage II disease who receive neoadjuvant chemotherapy, particularly if 1-3 lymph nodes remain pathologically involved, is insufficient to determine whether these patients should receive radiotherapy.
  • [MeSH-major] Breast Neoplasms / surgery. Chemotherapy, Adjuvant. Lymph Nodes / pathology. Lymphatic Metastasis
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Humans. Mastectomy. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):850-1; author reply 851 [12573777.001]
  • (PMID = 12095553.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / T32CA77050
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, Hillman SL, Farr GH Jr, Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR: Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2004 Jul 15;59(4):943-51
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
  • PURPOSE: This Phase III study was performed to determine whether twice-daily (b.i.d.) radiotherapy (RT) resulted in better survival than once-daily (q.d.
  • ) RT for patients with limited-stage small-cell lung cancer (LD-SCLC).
  • RT (50.4 Gy in 28 fractions) or split-course b.i.d.
  • RT (24 Gy in 16 fractions, a 2.5-week break, and 24 Gy in 16 fractions) to the chest.
  • No statistically significant differences were found in the rates of progression (p = 0.68), intrathoracic failure (p = 0.45), in-field failure (p = 0.62), or distant failure (p = 0.82) between the two treatment arms.
  • RT, the long-term survival was favorable, likely reflecting the positive influences of concurrent combined modality therapy and prophylactic cranial RT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Dose Fractionation. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):925-7 [15234025.001]
  • (PMID = 15234027.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 15083; United States / NCI NIH HHS / CA / CA 25224; United States / NCI NIH HHS / CA / CA 35101; United States / NCI NIH HHS / CA / CA 35103; United States / NCI NIH HHS / CA / CA 35113; United States / NCI NIH HHS / CA / CA 35195; United States / NCI NIH HHS / CA / CA 35269; United States / NCI NIH HHS / CA / CA 35272; United States / NCI NIH HHS / CA / CA 35415; United States / NCI NIH HHS / CA / CA 35448; United States / NCI NIH HHS / CA / CA 37404; United States / NCI NIH HHS / CA / CA 37417; United States / NCI NIH HHS / CA / CA 52352; United States / NCI NIH HHS / CA / CA 60276; United States / NCI NIH HHS / CA / CA 63826; United States / NCI NIH HHS / CA / CA 63848; United States / NCI NIH HHS / CA / CA 63849
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • METHODS AND MATERIALS: During the period 1971 to 1994, 94 patients with clinically staged HD, with favorable prognostic factors, were retrospectively reviewed.
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • There were 27 Stage IA and 67 Stage IIA patients.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.
  • CONCLUSIONS: Careful clinical staging of early, asymptomatic HD patients treated with mantle, splenic, and EFRT may obviate the need for exploratory laparotomy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Spleen
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


20. Schaefer PL, Marks RS, Mahoney MR, Sloan JA, Bauman MD, Tazelaar HD, Kugler JW, Mailliard JA, Ebbert LP, Wiesenfeld M: Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. Am J Clin Oncol; 2003 Jun;26(3):236-40
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
  • A randomized two-stage, phase II study was conducted to assess the antitumor activity of two different schedules of topotecan in the treatment of extensive-stage small-cell lung cancer (SCLC) in chemotherapy-naive patients.
  • Toxicity was predominantly hematologic with 92% (55/60) having greater than or equal to grade III neutropenia and 58% (35/60) reporting greater than or equal to grade III leukopenia for both IV schedules.
  • Median times to progression for the daily and continuous-infusion schedules are 5 months (90% CI: 4.4-7.2) and 2 months (90% CI: 1.1-2.1), respectively.
  • Fifty percent (30/60) of patients received second-line therapy with etoposide and cisplatin.
  • Forty-three percent (13/30) of patients who received second-line therapy achieved a confirmed response.
  • Topotecan showed significant activity in the treatment of extensive stage SCLC when administered as a brief daily IV repeated every 3 weeks.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12796591.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / CA60276
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R: Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol; 2001 Apr 15;19(8):2213-21
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
  • PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients.
  • PATIENTS AND METHODS: Stage IV breast cancer patients were randomized to receive as first-line chemotherapy either standard CEF (cyclophosphamide 600 mg/m(2), epirubicin 60 mg/m(2), and fluorouracil 600 mg/m(2)) administered every 21 days (CEF21) or accelerated-intensified CEF (cyclophosphamide 1,000 mg/m(2), epirubicin 80 mg/m(2), and fluorouracil 600 mg/m(2)) administered every 14 days (HD-CEF14) with the support of G-CSF.
  • Treatment was administered for eight cycles.
  • RESULTS: A total of 151 patients were randomized (74 patients on the CEF21 arm and 77 on the HD-CEF14 arm).
  • The dose-intensity actually administered was 93% and 86% of that planned, in CEF21- and HD-CEF14-treated patients, respectively.
  • Compared with the CEF21 arm, the dose-intensity increase in the HD-CEF14 arm was 80%.
  • Both nonhematologic and hematologic toxicities were higher in the HD-CEF14 arm than in the CEF21 arm.
  • During chemotherapy, four deaths occurred in the HD-CEF14 arm.
  • No difference in overall response rate (complete plus partial responses) was observed: 49% and 51% in the CEF21 and HD-CEF14 arms, respectively (P =.94).
  • A slightly non-statistically significant higher percentage of complete response was observed in the HD-CEF14 arm (20% v 15%).
  • The median time to progression was 14.3 and 12.8 months in the CEF21 and HD-CEF14 arms, respectively (P =.69).
  • Median overall survival was 32.7 and 27.2 months in the CEF21 and HD-CEF14 arms, respectively (P =.16).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11304774.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


22. Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, Oertel J, Diehl V, Engert A, German Hodgkin's Lymphoma Study Group: Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol; 2004 Jun 15;22(12):2424-9
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group.
  • PURPOSE: To investigate a new effective, nonleukemogenic polychemotherapy regimen, BAGCOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, gemcitabine) in a phase I/II dose-escalation study in patients with advanced-stage Hodgkin' s disease (HD).
  • PATIENTS AND METHODS: Patients in clinical stages IIB with risk factors III and IV were enrolled in this nonrandomized, multicenter trial aimed at defining the maximum-tolerated dose of gemcitabine within a modified escalated BEACOPP regimen.
  • A total of eight patients developed lung toxicity, mainly pneumonitis (six of eight), which led to the termination of the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Hodgkin Disease / diet therapy. Lung Diseases / chemically induced
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15136597.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; VB0R961HZT / Prednisone
  •  go-up   go-down


23. Kochbati L, Boussen H, Benna F, Belhaj Ali Z, Gammoudi A, Bouaouina N, Besbes M, Ghilen L, Rahal K, Maalej M: [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz]. Cancer Radiother; 2003 Oct;7(5):302-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
  • [Transliterated title] Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie. Etude rétrospective à propos de 26 cas observés à l'institut Salah-Azaïz.
  • PURPOSE: To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.
  • METHODS AND PATIENTS: We consider as second cancer all tumours other than HD observed in patients after treatment for HD.
  • RESULTS: Twenty-five patients among 614 treated for HD between 1975 and 1991 developed 26 secondary tumours (4.2%).
  • Mean age at the diagnosis of HD was 32.5 years (12-56).
  • HD was stage II (eight cases), stage III (14) and stage IV in three.
  • The first treatment was combined chemotherapy and radiotherapy in 22 cases and only chemotherapy in three cases (stage IV).
  • Mean dose was 41.3 Gy (2 Gy/fraction in 21 and 3.3 in one).
  • Chemotherapy was MOPP (13), MOPP and vinblastine (four), MOPP-ABVD (five), ABVD (two) and vinblastine only in one.
  • There was five acute myeloid leukaemia, two digestive non-Hodgkin lymphomas, five nodal high-grade lymphomas, three breast cancers (one in man associated with thyroid cancer), five lung cancers (three non-small cell and two of small cell type), two gastric tumours and one rectal cancer, one synovialosarcoma of the knee and one malignant Schwannoma of the neck.
  • CONCLUSION: Second cancer risk after treatment for HD is not low.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Incidence. Male. Mechlorethamine / adverse effects. Middle Aged. Prednisone / adverse effects. Procarbazine / adverse effects. Retrospective Studies. Risk Factors. Tunisia / epidemiology. Vinblastine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522350.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


24. Balwierz W, Moryl-Bujakowska A, Depowska T, Klekawka T, Rokicka-Milewska R, Sopylo B, Kolakowska-Mrozowska B, Chybicka A, Boguslawska-Jaworska J, Pisarek J, Ras M, Sonta-Jakimczyk D, Janik-Moszant A, Kolecki P, Kaczmarek-Kanold M, Kowalczyk J, Odoj T, Matysiak M, Newecka-Samol T, Balcerska A, Adamkiewicz-Drozynska E, Wysocki M, Kurylak A: [Treatment regimen for children and adolescents with Hodgkin's disease designed to decrease late complications of radiotherapy]. Med Wieku Rozwoj; 2001 Jul-Sep;5(3 Suppl 1):25-35
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment regimen for children and adolescents with Hodgkin's disease designed to decrease late complications of radiotherapy].
  • Between 1997 to 1999 in 9 centres of the Polish Paediatlic Leukemia/Lymphoma Study Group, 167 children and adolescents (aged 2-19 years) with stage 1 to IV Hodgkin's disease (HD) were treated according to a regimen with a limited use of radiotherapy (RT).
  • All patients received B-DOPA and MVPP chemotherapy.
  • The number of cycles of chemotherapy was adjusted in respective risk groups.
  • In 13 children with stage IA and IIA disease with favourable prognostic factors chemotherapy alone was used.
  • In other patients the dose of RT applied to lymphatic regions was 15-46,4 Gy.
  • In case of a small tumour at presentation and good response to initial chemotherapy the RT dose was 15-16 Gy.
  • In other cases doses of 25-30 Gy were planned.
  • The use of higher doses, particularly exceeding 35 Gy, in eleven patients, was not justified.
  • Among all the 167 patients, three oftliem (1.2%) with advanced disease (Stage III-1V) did not achieve first remission.
  • All 13 children in whom chemotherapy alone was used remain in first remission.
  • In the group of children who received RT in the dose of 15-16 Gy relapse occurred in one child.
  • Our preliminary analysis indicates that limited use of RT in selected cases of HD in children and adolescents did not show worse results of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Recurrence. Remission Induction. Risk. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004149.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


25. Szelényi H, Kreuser ED, Keilholz U, Menssen HD, Keitel-Wittig C, Siehl J, Knauf W, Thiel E: Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. Ann Oncol; 2001 Jan;12(1):105-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma.
  • BACKGROUND: Patients with advanced multiple myeloma (stage III or progressive myeloma) received the CAD protocol every three weeks: cyclophosphamide 200 mg/m2 i.v.
  • According to Durie-Salmon 44 patients were in stage III, 2 in stage II; 6 patients had renal insufficiency (stage B).
  • RESULTS: Remission rates were as follows: complete remission 4%, partial remission 70%, minimal change 11%, no change 11%, progressive disease 4%.
  • After an observation time of 14 months the median progression free interval for 33 patients not treated with subsequent high-dose chemotherapy with stem-cell support was more than 14 months.
  • Overall, treatment was well tolerated.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11249035.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


26. Economopoulos T, Fountzilas G, Dimopoulos MA, Papageorgiou S, Xiros N, Kalantzis D, Dervenoulas J, Raptis S: Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study. Eur J Haematol; 2003 Oct;71(4):257-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study.
  • The purpose of this prospective phase II trial was to investigate the safety and efficacy of a modified baseline BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen in the treatment of intermediate and advanced stage Hodgkin's disease (HD).
  • From October 1997 to November 2001, 51 consecutive, previously untreated patients with stage IIA (bulky), IIB, III, and IV disease were treated with a modified baseline BEACOPP regimen with the etoposide administered i.v. on day 1 and orally at a dose of 100 mg/m2, on days 2 and 3.
  • Each patient was scheduled to receive eight courses of BEACOPP with consolidation radiotherapy to bulky (> or =5 cm) or residual disease.
  • There were 25 males and 26 females with a median age of 32 yr (16-65 yr); 80.3% of the patients had nodular sclerosis HD, 41% had bulky disease (> or =5 cm), 10 were in stage IIA (bulky > or =10 cm), 15 in stage IIB, 19 in stage III, and seven in stage IV.
  • No significant difference in overall response rate was observed between patients with: (i) 0-2 vs. > or =3 negative prognostic factors, (ii) in stage II vs. stages III/IV, LDH level, and bulky disease.
  • With a median follow up period of 39.5 months, actuarial 3-yr survival rate is 82% and time to progression rate 72.5%.
  • Treatment with this combination was well tolerated.
  • The results of the present study demonstrate that the modified baseline BEACOPP regimen with radiotherapy used in our patients was well tolerated and effective therapy for intermediate and advanced stage HD.
  • Further follow up time is required to evaluate long-term toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Prednisone / therapeutic use. Procarbazine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12950234.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


27. Fitoussi, Eghbali H, Tchen N, Berjon JP, Soubeyran P, Hoerni B: Semen analysis and cryoconservation before treatment in Hodgkin's disease. Ann Oncol; 2000 Jun;11(6):679-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semen analysis and cryoconservation before treatment in Hodgkin's disease.
  • BACKGROUND: The prophylaxis of the late effects of chemotherapy and radiotherapy has become one of the major concerns in the management of Hodgkin's disease (HD).
  • PATIENTS AND METHODS: To evaluate the semen quality of patients with HD and the outcome of insemination, we reviewed spermograms of patients who underwent SP before any treatment.
  • 2) HD of any stage;.
  • 3) informed about male sterility after HD treatment;.
  • All patients underwent an initial chemotherapy.
  • Pretherapeutic staging of HD revealed 38 stage I (40%), 38 II (38%), 14 III (15%) and 4 IV (4%).
  • The analysis of semen quality and spermatozoid amount according to various parameters failed to find a correlation with stage, B symptoms, age, or biologic data (LDH, WBC, platelets, ESR).
  • CONCLUSIONS: The low rate of success with cryopreserved semen in these cases suggests the need for a more careful design of non-toxic chemotherapy regimens in combined modality treatment.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10942055.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A, Participating Centers: Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol; 2002 Oct;13(10):1628-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
  • BACKGROUND: An important variable affecting outcome in relapsed and refractory Hodgkin's disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume before high-dose chemotherapy (HDCT) and autologous stem cell transplantation.
  • Currently, the optimal salvage chemotherapy regimen for these patients is unclear.
  • Since dexamethasone/cisplatin/cytarabine (DHAP) given at 3-4 week intervals has been shown to be very effective in patients with relapsed aggressive non-Hodgkin's lymphoma, we evaluated this regimen given at a median of 16-day intervals in patients with relapsed and refractory HD.
  • PATIENTS AND METHODS: Patients with relapsed or refractory HD were treated with two cycles of DHAP [dexamethasone 40 mg intravenously (i.v.) day 1-4, cisplatin 100 mg/m(2) i.v. as 24-h continuous infusion day 1, and cytarabine 2 g/m(2) i.v.
  • Forty-two percent of the patients had late relapse, 29% early relapse, 12% multiple relapse and 16% primary progressive/refractory disease.
  • The RRs for patients with late, early, multiple and progressive HD were 91%, 93%, 92% and 65%, respectively.
  • Using the chi-square test for independence, remission status (relapsed HD versus progressive HD) and stage at relapse (stage I/II versus stage III/IV) were significant factors for response to DHAP.
  • Neither severe infections nor treatment-related deaths occurred.
  • CONCLUSIONS: A brief tumor-reducing program with two cycles of DHAP given in short intervals supported by G-CSF is effective and well-tolerated in patients with relapsed and refractory HD.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377653.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol; 2006 Jun;17(6):914-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
  • BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART).
  • MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004.
  • RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness.
  • Fifty-nine of 66 patients (89.4%) underwent curative intended chemotherapy.
  • Three-year mortality was significantly higher in patients without complete remission (HR 4.40, CI 1.77-10.99), with stage III/IV HD (HR 4.64, CI 1.31-16.49) and with CD4 cells <200/microl (HR 2.69, CI 0.99-7.33).
  • CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565210.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


30. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol; 2002 Jan 01;20(1):221-30
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
  • PURPOSE: To evaluate salvage treatment outcome of patients with relapsed Hodgkin's disease (HD) and to distinguish different risk groups using identified prognostic factors.
  • PATIENTS AND METHODS: From 4,754 patients registered in the German Hodgkin's Lymphoma Study Group (GHSG) database between 1988 and 1999, 422 patients with early (n = 170) or late (n = 252) relapsed HD were identified.
  • One hundred seven patients (25%) relapsed after radiotherapy (RT) for early stages, 133 patients (32%) after combined-modality therapy for intermediate stages, and 182 patients (43%) after chemotherapy (CT) and RT to initial bulky disease or residual lymphoma for advanced stages.
  • At relapse, characteristics of these 422 patients (median age, 38 years; range, 17 to 77) were stage III/IV, 45%; B symptoms, 24%; elevated erythrocyte sedimentation rate, 29%; anemia, 13%; and Karnofsky performance score, less than 90 in 13%.
  • At first relapse, salvage treatment was RT in 13%, CT in 54%, and high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) in 33%.
  • RESULTS: Median follow-up time after relapse was 45 months.
  • In multivariate analysis, independent risk factors were time to relapse, clinical stage at relapse, and anemia at relapse.
  • CONCLUSION: In the GHSG database, time to relapse and clinical stage and anemia at relapse are relevant factors and can be used to form a prognostic score for HD patients at relapse.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Salvage Therapy
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Aged. Analysis of Variance. Combined Modality Therapy. Female. Follow-Up Studies. Germany / epidemiology. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Recurrence. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11773173.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Lee JK, Tsai SC, Ho YJ, Changlai SP, Kao CH: Technetium-99m tetrofosmin scintigraphy for detecting malignant lymphoma. Anticancer Res; 2001 Mar-Apr;21(2B):1509-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technetium-99m tetrofosmin scintigraphy for detecting malignant lymphoma.
  • In the study, before any chemotherapy, 50 patients with malignant lymphoma underwent Tc-TF scintigraphy, which was performed 10 minutes after intravenous injection of 20 mCt Tc-TF.
  • Tc-TF scintigraphy detected malignant lymphoma in 44 (88%) patients.
  • However, there were no significant differences in the incidences of positive and negative Tc-TF scintigraphic results between female versus male patients, HD versus NHL patients, stage I-II versus stage III-IV patients, age > 40 years versus < or = 40 years patients and patients with B symptoms false-negative results occurred in 4 (8%) infradiaphragmatic malignant lymphoma.
  • We conclude patients with that Tc-TF scintigraphy appears suitable for detecting malignant lymphoma, especially supradiaphragmatic lesions.
  • [MeSH-major] Lymphoma / diagnosis. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11396241.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


32. Renedo RJ, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP: Avascular necrosis of the femoral head in patients with Hodgkin's disease. Hip Int; 2010 Oct-Dec;20(4):473-81
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of the femoral head in patients with Hodgkin's disease.
  • Avascular necrosis of the femoral head (ANFH) is a rare complication that may occur in patients diagnosed with Hodgkin's Disease (HD), as a result of treatment.
  • A review was made of 315 cases of HD treated with systemic chemotherapy associated with high doses of steroids and radiation therapy and 18 patients (5.71%) were found to have developed ANFH during treatment.
  • The mean follow-up time for chemotherapy was 40 months (range 20-110 months) with an average dose of prednisone of 8.45 g (range 3.20 - 18.50).
  • In 8 cases (44.44%) forage associated with IES was performed as the initial treatment option and 6 of these cases were found to be in Ficat stage II (75%), 1 was found to be in stage III (12.55%) and another in stage IV (12.5%).
  • In 2 cases, the central decompression technique was used (Simple Forage); both were in Ficat stage II.
  • In the other 8 cases, a total hip arthroplasty (THA) was chosen as the initial treatment option, with 3 of these patients in Ficat stage III and 5 in Ficat stage IV.
  • The clinical outcomes (time to postoperative pain, time to radiological failure, and time to arthroplasty from the forage) following surgical management using the forage-biopsy technique with and without internal electrostimulation (IES) were recorded.
  • We observed that treatment with Forage + IES was better than simple Forage in stages below III in patients with Hodgkin's Disease.
  • We considered that in Ficat stage III and IV arthroplasty (THA) was the better option.
  • [MeSH-major] Femur Head Necrosis / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arthroplasty, Replacement, Hip. Decompression, Surgical. Electric Stimulation Therapy. Female. Glucocorticoids / adverse effects. Humans. Male. Middle Aged. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157752.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


33. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • The optimal chemotherapy regimen needs to be investigated.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • Grade 3-4 myelosuppression occurred in most patients and were recovered by active support care and did not affect next course of chemotherapy.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


34. Saif MW, Hamilton JM, Allegra CJ: Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease. Leuk Lymphoma; 2000 Oct;39(3-4):421-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease.
  • Varicella zoster (V-Z) infections are common among patients with hematological malignancies, particularly Hodgkin's disease (HD).
  • The common denominator in both HD and V-Z infections is immunosuppression.
  • Most of V-Z infections occur in patients with HD during the remission period, who have mixed cellularity sub-type, with stage III disease and who have received combined chemo-radiation therapy.
  • The authors describe a case of HD who developed V-Z meningitis preceeded by superficial thrombophlebitis of upper extremities during the period of active chemotherapy.
  • [MeSH-major] Hodgkin Disease / virology. Meningitis, Viral / chemically induced. Thrombophlebitis / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Humans. Immunocompromised Host. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342324.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


35. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK: Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol; 2006 Sep 1;24(25):4116-22
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
  • PURPOSE: To estimate the clinical benefits and cost effectiveness of computed tomography (CT) in the follow-up of patients with complete response (CR) after treatment for Hodgkin's disease (HD).
  • PATIENTS AND METHODS: We developed a decision-analytic model to evaluate follow-up strategies for two hypothetical cohorts of 25-year-old patients with stage I-II or stage III-IV HD, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine-based chemotherapy with or without radiation therapy, respectively.
  • With adjustments for quality of life, we found a decrement in quality-adjusted life expectancy for early-stage patients followed with CT compared with non-CT modalities.
  • For advanced-stage patients, annual CT for 5 years is associated with a very small quality-adjusted survival gain over non-CT follow-up with an incremental cost-effectiveness ratio of 9,042,300 dollars/QALY.
  • CONCLUSION: Our analysis suggests that routine CT should not be used in the surveillance of asymptomatic patients in CR after treatment for HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Decision Support Techniques. Hodgkin Disease / economics. Hodgkin Disease / radiography. Population Surveillance / methods. Tomography, X-Ray Computed / economics
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cost-Benefit Analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Life Expectancy. Markov Chains. Neoplasm Staging. Predictive Value of Tests. Quality-Adjusted Life Years. Sensitivity and Specificity. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943528.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R25 CA57711-11
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


36. Staib L, Gottwald T, Lehnert T, Ruf G, Sturm J, Becker HD, Farthmann E, Herfarth C, Post S, Trede M, Beger HG: Sphincter-saving treatment in epidermoid anal cancer: cooperative analysis of 142 patients in five German university surgical centers. Int J Colorectal Dis; 2000 Nov;15(5-6):282-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-saving treatment in epidermoid anal cancer: cooperative analysis of 142 patients in five German university surgical centers.
  • Five southern German university centers cooperated in comparing the effect of surgical vs. nonsurgical therapy strategies on survival and sphincter preservation in the treatment of anal cancer.
  • A standardized questionnaire was used to evaluate retrospectively (mean follow-up 30 months) treatment strategy and outcome (survival, colostomy rate, colostomy-free survival) in patients treated between 1987 and 1996.
  • Of the 142 patients 65% had squamous cell, 20% basaloid, 6% adeno-, and 1% undifferentiated carcinoma (8% histology not recorded); 9% were classified in UICC stage I, 37% in stage II, 25% in stage III, and 4% in stage IV (25% not recorded).
  • Primary treatment consisted of local excision (10%), excision plus radio- and/or chemotherapy (17%), radiotherapy (20%), radiochemotherapy (28%), or colostomy with or without resection, radiotherapy, and chemotherapy (23%).
  • We observed no difference between these treatment groups in overall (P = 0.43) or colostomy-free survival (P = 0.14, log-rank).
  • Mean overall survival (in months) was 42 in stage I, 38 in stage II, and 25 in stage III (P = 0.0013); mean colostomy-free survival was 36 in stage I, 26 in stage II, and 16 in stage III (P = 0.0021, log-rank).
  • Outcome was not significantly related to therapeutic strategy (surgery or radio-chemotherapy.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma / mortality. Carcinoma / surgery. Carcinoma / therapy. Clinical Trials as Topic. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multicenter Studies as Topic. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11151431.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Rueffer U, Breuer K, Josting A, Lathan B, Sieber M, Manzke O, Grotenhermen FJ, Tesch H, Bredenfeld H, Koch P, Nisters-Backes H, Wolf J, Engert A, Diehl V: Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol; 2001 Sep;12(9):1307-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.
  • Infertility after treatment of patients with Hodgkin's disease (HD) is considered as a side effect of alkylating agent containing chemotherapy regimens.
  • To investigate whether gonadal failure is related primarily to the toxic effect of chemotherapy or rather to the disease itself, we investigated the fertility status before the onset of treatment.
  • PATIENTS AND METHODS: Semen quality and hormonal status were evaluated in 158 patients with first diagnosis of HD enrolled into trials of the German Hodgkin Lymphoma Study Group (GHSG).
  • Twenty patients (13%) were classified as early stage HD, 63 patients (40%) as intermediate stage, and 75 patients (47%)) as advanced stage according GHSG grading.
  • RESULTS: Prior to treatment, severe damage of fertility, i.e.. azoospermia and oligoasthenoteratospermia (OAT-syndrome) was found in 13 (8%) and 20 patients (13%), respectively.
  • Thus, III patients (70%) showed semen abnormalities before the onset of treatment.
  • In a multivariate analysis elevated ESR (P < 0.003) and advanced stage of disease (P < 0.01) could be distinguished as prognostic factors for severe damage of fertility.
  • No correlation was found between pre-therapeutic gonadotropine levels and fertility status.
  • CONCLUSION: Patients with HD have an increased risk for inadequate semen quality even prior to treatment.
  • Infertility is more frequent in patients with elevated ESR and advanced stage of disease.
  • This association demonstrates the predominant influence of the disease on fertility.
  • Assuming HD is the major initial cause for infertility efforts should be made to identify new non-gonadal toxic chemotherapies to be able to regain fertility after effective therapy.
  • Further investigations have to be performed to clarify mechanisms inducing fertility defects in patients with HD.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2002 Feb;13(2):333 [11886015.001]
  • (PMID = 11697845.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


38. Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric F, Schechter NR, Sahin AA, Middleton LP, Buchholz TA: Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys; 2004 Jul 15;59(4):1074-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We separately analyzed the outcome for those initially treated with surgery (n = 265) and those receiving neoadjuvant chemotherapy (n = 74).
  • For the patients treated with neoadjuvant chemotherapy, the independent factors were clinical Stage III (rate, 48%, OR = 3.1, p = 0.03), more than one positive SLN (rate, 37-67%, OR = 4.8, p = 0.03), and LVSI (rate, 62%, OR = 8.1, p = 0.02).
  • This approach is also reasonable for patients treated with neoadjuvant chemotherapy who have Stage II disease, no LVSI, and only one positive SLN.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Chemotherapy, Adjuvant. Clavicle. Humans. Lymph Node Excision. Lymphatic Irradiation. Middle Aged. Odds Ratio. Regression Analysis. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234041.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Initial stage I:II:III:IV:unknown was 15:34:33:42:3.
  • Median prior chemotherapy cycles were six [<6 (17 patients), 6-8 (90 patients), >8 (20 patients)].
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


40. Chisesi T, Federico M, Levis A, Deliliers GL, Gobbi PG, Santini G, Luminari S, Linfomi MB, Intergruppo Italiano Linfomi: ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol; 2002;13 Suppl 1:102-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
  • BACKGROUND: Between January 1996 and April 2000, 355 patients with advanced Hodgkin's disease (HD) (stage II bulky disease, III and IV) were enrolled in a prospective, multicentre, randomised trial aimed at comparing the efficacy of two new promising regimens: Stanford V and MEC hybrid.
  • Radiotherapy was planned at the end of induction therapy on residual masses or on sites of previous bulky lesions.
  • RESULTS: After induction therapy a complete response (CR) was observed in 93, 89 and 74% of patients treated with MEC, ABVD and Stanford V, respectively, with a statistically significant difference (P = 0.013) between the arms.
  • Toxicity was comparable in the three treatment arms.
  • Notwithstanding the short follow-up, these results seem to be very impressive in defining the best standard treatment for HD for this subset of patients.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078888.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone
  •  go-up   go-down


41. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F: Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma; 2001 May;41(5-6):535-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome.
  • We report the frequency, presenting characteristics, progression-free survival, event-free survival, overall survival and AIDS-free survival of patients with previously untreated Hodgkin's disease (HD) in the setting of infection by human immunodeficiency virus (HIV).
  • Anderson Cancer Center between July 1985 and August 1999 with HD and HIV infection.
  • All available records were reviewed to determine presentation, clinical characteristics, treatment outcome, progression-free survival and overall survival.
  • We identified 887 patients with HD and 3,500 with Non-Hodgkin's Lymphoma (NHL).
  • The ratio of NHL to HD in HIV-negative versus HIV-positive patients was 3.9 versus 6.9, respectively.
  • There were 14 HIV-positive patients with HD and 97 with NHL.
  • The median age of the HIV-positive HD patients was 33 years, and 13 were male.
  • Three patients had Acquired Immune Deficiency syndrome (AIDS) at the time of HD diagnosis, and seven had B-symptoms.
  • Ann Arbor stage was I in one, II in three, III in four and IV in six patients.
  • Mixed cellularity histology was seen in eight, bone marrow involvement in five and extranodal disease in seven patients.
  • All patients received some antiretroviral therapy, but it was variable over the years.
  • Six patients died of complications arising from HIV infection, including one patient who had preexisting AIDS at HD presentation.
  • Two patients died of HD, without developing other conditions diagnostic of AIDS.
  • We conclude that in our referral patient population HIV infection is associated with preferential development of NHL rather than HD, which appears curable with standard treatment regimens.
  • Since HIV-related deaths exceed those caused by HD, future investigation should focus on integration of chemotherapy and highly active antiretroviral therapy.
  • [MeSH-major] Hodgkin Disease / virology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Actuarial Analysis. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiviral Agents / administration & dosage. Female. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378571.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


42. Potapov EV, Hennig F, Wagner FD, Volk HD, Sodian R, Hausmann H, Lehmkuhl HB, Hetzer R: Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. Eur J Cardiothorac Surg; 2005 May;27(5):899-905
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: In patients with inotrope-dependent end-stage heart failure the timely application of the most suitable treatment, i.e. heart transplantation, implantation of a ventricular assist device or conservative treatment, is a key issue for therapeutic success.
  • METHODS: Seventy-six inotrope-dependent patients with end-stage heart failure were enrolled.
  • The patients were retrospectively divided into groups with regard to the following end-points: Group I-deterioration into cardiogenic shock after an initially stable clinical course (n=26); Group II-stable clinical course without deterioration into cardiogenic (n=41); Group III-weaning from inotropic support (n=9).
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / blood. C-Reactive Protein / analysis. Dobutamine / administration & dosage. Dobutamine / therapeutic use. Dopamine / administration & dosage. Dopamine / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Enoximone / administration & dosage. Enoximone / therapeutic use. Epidemiologic Methods. Epinephrine / administration & dosage. Epinephrine / therapeutic use. Female. Humans. Male. Middle Aged. Natriuretic Peptide, Brain / blood. Nerve Tissue Proteins / blood. Norepinephrine / administration & dosage. Norepinephrine / therapeutic use. Peptide Fragments / blood. Prognosis. Shock, Cardiogenic / blood. Shock, Cardiogenic / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848333.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / E-Selectin; 0 / Natriuretic Peptides; 0 / Nerve Tissue Proteins; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain; 3S12J47372 / Dobutamine; 9007-41-4 / C-Reactive Protein; C7Z4ITI7L7 / Enoximone; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


43. Re A, Casari S, Cattaneo C, Facchetti F, Cadeo G, Carosi G, Rossi G: Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer; 2001 Dec 1;92(11):2739-45
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma.
  • BACKGROUND: Unlike aggressive non-Hodgkin lymphoma (NHL), Hodgkin disease (HD) develops rarely in patients who are infected by human immunodeficiency virus (HIV), and its characteristics are not well defined.
  • The authors analyzed the clinicopathologic and prognostic features from a consecutive series of patients with HIV-associated HD who were observed at their institution and compared them with the features observed in a concurrent series of patients with systemic HIV-related NHL.
  • Their demographic, immunologic, and clinicopathologic features; responses to treatment; and outcomes were compared with those of 98 patients with systemic NHL of aggressive histology who were diagnosed during the same period and with 165 HIV negative patients with HD.
  • RESULTS: HIV-associated HD and NHL occurred in patients with similar age, gender, HIV risk factors, degree of immunodeficiency, and incidence of previous acquired immunodeficiency syndrome.
  • The clinical presentation of HIV-associated HD was atypical and was more aggressive than in HIV negative patients (mediastinal involvement, 11%; Stage III-IV, 84%; B symptoms, 83%).
  • It was similar to HIV-related NHL, except for the frequency of extralymph node disease, which was seen less frequently in patients who had HD (56%) compared with patients who had NHL (82%; P = 0.025), and the frequency of bone marrow involvement, which was unexpectedly higher in patients who had HD (50%) compared with patients who had NHL (20%; P = 0.011).
  • Potentially curative treatment was administered to 77% of patients with HD and 66% of patients with NHL.
  • Complete remission and disease recurrence rates as well as disease free and overall survival rates did not differ significantly, with estimated overall survival at 5 years of 24% in patients with HD and 23% in patients with NHL.
  • CONCLUSIONS: HIV-associated HD is an aggressive disease with demographic, clinical, and prognostic features nearly identical to those of HIV-related NHL.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. HIV Infections / complications. Hodgkin Disease / etiology
  • [MeSH-minor] Adult. Female. Humans. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome


44. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • METHODS AND MATERIALS: Between 1982 and 2007, 170 patients with HD with median age of 12 years (range 3-40), (68 females, 102 males), were included in this retrospective study.
  • The clinical stage (CS) distribution was CS I in 1 patient (0.6%), CS II in 86 (50.5%), CS III in 77 (45.3%) and CS IV in 6 (3.5%) patients.
  • The overall treatment consisted of both EFRT and CHT.
  • The daily dose was 1.5-2 Gy, the total dose for EFRT was 20-40 Gy.
  • RESULTS: Follow-up extended from a minimum of 0,3 years to maximum 25,7 years, with a median observation time 12 years.The 5-, 10-, 15-, and 25-year overall survival (OS) in the whole group was 93% : 86% : 82% : 82%, respectively.
  • The following factors were analyzed for their prognostic influence: age, gender, stage, histologic subtype at first diagnosis, sites of involvement, number of involved lymph node areas, B symptoms, hepatosplenomegaly, anemia, elevated serum LDH, daily dose, total dose, boost and technique used in EFRT.
  • In univariate analysis, independent risk factors were gender (p < 0.001), stage (IIB: IIIA) (p = 0.03), mediastinal involvement (p = 0.03), daily dose (p = 0.01) and total dose (p = 0.02).
  • In multivariate analysis, independent risk factors age < or = 15 years (p < 0.001), male gender (p = 0.005), daily dose < or = 1.5 Gy (p = 0.009), and total dose 26-30 Gy (p = 0.048) were found to positively affect OS.
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


45. Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA, Provencio M, de Lafontan B, de la Rochefordiere A, Cellai E, Graic Y, Kerbrat P, Alzieu C, Teissier E, Dilhuydy JM, Mignotte H, Velten M: Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol; 2001 Jun;59(3):247-55
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases.
  • PURPOSE: To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods.
  • MATERIALS AND METHODS: In a retrospective multicentric analysis, 117 women and two men treated for HD subsequently developed 133 BCs.
  • The median age at diagnosis of HD was 24 years.
  • The HD stages were stage I in 25 cases (21%), stage II in 70 cases (59%), stage III in 13 cases (11%), stage IV in six cases (5%) and not specified in five cases (4%).
  • Radiotherapy (RT) was used alone in 74 patients (63%) and combined modalities with chemotherapy (CT) was used in 43 patients (37%).
  • Sixteen patients (12%) developed isolated local recurrence.
  • Thirty-nine patients (31.7%) developed metastases and 34 died; 38 are in complete remission whereas five died of intercurrent disease.
  • The 5-year disease-specific survival rate was 65.1%.
  • The 5-year disease-specific survival rates for the pN0, pN1-3 and pN>3 groups were 91, 66 and 15%, respectively (P<0.0001), and 100, 88, and 64% for the TIS, T1 and T2.
  • These secondary BC are of two types: a large number of aggressive tumours with a very unfavourable prognosis (especially in the case of pN>3 and/or T3T4), and many tumours with a 'slow spreading' such as DCIS and microinvasive lesions.
  • These lesions developed especially in patients treated exclusively by RT.
  • CONCLUSIONS: The young women and girls treated for HD should be carefully monitored in the long-term by clinical examination, mammography and ultrasonography.
  • Subsequent mammographies should be performed every 2 years or each year, depending on the characteristics of the breast tissue (e.g. density) and especially in the case of an association with other BC risk factors.
  • This screening seems of importance due to excellent prognosis in our T(1S)T(1) groups, and the possibility of offering these young women a conservative treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / etiology. Breast Neoplasms, Male / etiology. Hodgkin Disease / complications. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Confidence Intervals. Female. Follow-Up Studies. Humans. Italy / epidemiology. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Prognosis. Retrospective Studies. Risk Factors. Spain / epidemiology. Survival Analysis. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11369065.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


46. Yang JJ, Park SK, Cho LY, Han W, Park B, Kim H, Lee KS, Hahn SK, Cho SI, Ahn SH, Noh DY, Korean Breast Cancer Society: Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database. Clin Ther; 2010 Jun;32(6):1122-38
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
  • OBJECTIVE: This study aimed to evaluate the cost-effectiveness of postoperative adjuvant tamoxifen therapy using data from a Korean breast cancer registry.
  • Women with stage I, II, or III breast cancer (diagnosed between 1981 and 2005), for whom information about tamoxifen use (20 mg/d for 5 years) and estrogen-receptor and/or progesterone-receptor status was available, were included.
  • Using a decision analytic model based on standard clinical flow, incremental cost-effectiveness ratios (ICERs) for overall survival were calculated with stratification by disease stage and hormone-receptor status.
  • Among those with stage I or II breast cancer, ICERs for estrogen-receptor positive (ER+)/progesterone-receptor positive (PR+) tamoxifen users ranged from $739 to $1939.
  • In contrast to those with stage I or II disease, tamoxifen use among patients with stage III disease was cost-effective regardless of hormone-receptor status.
  • CONCLUSIONS: In this analysis, postoperative adjuvant tamoxifen use was cost-effective for stage I or II ER+ and/or PR+ breast cancer, but not for ER-/PR- disease.
  • Tamoxifen therapy appeared to be cost-effective for patients with stage III breast cancer regardless of hormone-receptor status.
  • [MeSH-major] Antineoplastic Agents, Hormonal / economics. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Tamoxifen / economics. Tamoxifen / therapeutic use
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cohort Studies. Cost-Benefit Analysis. Female. Humans. Korea. Middle Aged. Neoplasm Recurrence, Local. Registries. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20637966.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Investigator] Ahn SH; Bae JW; Bae YT; Baek JW; Bong JG; Cha KH; Chang ES; Chang IT; Chang SS; Cho JW; Cho SH; Cho YU; Choi JW; Choi KJ; Choi MS; Choi SI; Choi SY; Goo GS; Han SH; Han W; Hong SJ; Hwang JY; Hyun TI; Im MG; Jegal YJ; Joh YG; Jun SY; Jung BW; Jung J; Jung JH; Jung KH; Jung PJ; Jung SH; Jung SS; Jung YH; Jung YS; Kang DH; Kang HJ; Kang YI; Kang YJ; Keum JH; Kim DY; Kim HJ; Kim JG; Kim JH; Kim JS; Kim JS; Kim KC; Kim SC; Kim SH; Kim SI; Kim SJ; Kim SW; Kim SW; Kim SY; Kim SY; Kim YS; Ko BK; Ko SS; Koh SH; Koo BH; Koo JY; Kwak BS; Lee CH; Lee CH; Lee DH; Lee DS; Lee ES; Lee GS; Lee HD; Lee HS; Lee JC; Lee JH; Lee JK; Lee JS; Lee JY; Lee KM; Lee KP; Lee KS; Lee KY; Lee MH; Lee RA; Lee SC; Lee SJ; Lee SK; Lee W; Lee YH; Leu JW; Lim CH; Lim CW; Moon BI; Nam SJ; Nam YS; Noh DY; Noh WC; Oh SJ; Oh SS; Pae WK; Paik IW; Paik NS; Park BG; Park BW; Park CH; Park HB; Park HY; Park JH; Park KH; Park SJ; Park ST; Park SW; Park WC; Park YK; Park YK; Seo HS; Seo KH; Seo YJ; Sin YS; Son BH; Son GS; Song BJ; Song KH; Song YJ; Suh YJ; Won JM; Woo DH; Yang DH; Yang JH; Yoo KY; Yoo SY; Yoon HS; Yoon JH; Yoon SO
  •  go-up   go-down


47. Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM: Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat; 2005 Jul;12(4):386-92
Hazardous Substances Data Bank. LAMIVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
  • We evaluated the effectiveness and the determinants of early mortality of lamivudine treatment in patients with HBV-related decompensated LC.
  • Univariate analysis revealed that the total bilirubin (P = 0.008), prothrombin time (P = 0.004), Child-Turcotte-Pugh score (P = 0.005), the model of efd-stage liver disease score (P = 0.004) and stage III hepatic encephalopathy (P = 0.001) were predictive factors of early mortality.
  • Multivariate analysis revealed that the independent factor associated with early mortality was stage III encephalopathy.
  • Among 22 patients, liver function improved markedly after lamivudine therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B, Chronic / drug therapy. Lamivudine / therapeutic use. Liver Cirrhosis / drug therapy
  • [MeSH-minor] Adenine / analogs & derivatives. Adenine / therapeutic use. Adult. Aged. Drug Resistance, Viral / genetics. Female. Hepatic Encephalopathy. Hepatitis B virus / drug effects. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Humans. Male. Middle Aged. Mutation. Organophosphonates / therapeutic use. Survival Analysis. Taiwan

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Adefovir .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985009.001).
  • [ISSN] 1352-0504
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 2T8Q726O95 / Lamivudine; 6GQP90I798 / adefovir; JAC85A2161 / Adenine
  •  go-up   go-down






Advertisement